Skip to Main Content
Try STAT+ TODAY
Trending:
Pharmalot
Coronavirus
Biotech
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Alnylam’s longtime CEO to depart, new leader named

  • Kate Sheridan

By Kate Sheridan Oct. 28, 2021

Reprints
Dr. John Maraganore
Alnylam CEO John Maraganore is leaving the company on Dec. 31. Lane Turner/The Boston Globe

John Maraganore, who has been the chief executive of Alnylam for nearly 19 years, is stepping down on Dec. 31, Alnylam announced Thursday. Yvonne Greenstreet has been named as the next CEO.

This is the second top executive to leave Alnylam and the third significant change in the company’s leadership in the last 13 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Kate Sheridan

Kate Sheridan

Research Reporter

Kate collects and analyzes documents, data, and other information for biotech, health tech, science, and politics stories.

Tags

Create a display name to comment

This name will appear with your comment

People with terminal cancer need to know they are…
People with terminal cancer need to know they are dying. Doctors shouldn’t withhold that information
Your questions on the new Covid vaccine boosters answered
Your questions on the new Covid vaccine boosters answered
Comparing the Pfizer and Moderna Covid vaccines for young…
Comparing the Pfizer and Moderna Covid vaccines for young children
Pharmalittle: Illumina faces more challenges after winning FTC case;…
Pharmalittle: Illumina faces more challenges after winning FTC case; Novo Nordisk buys Forma Therapeutics
Illumina wins case against FTC in bid to hold…
Illumina wins case against FTC in bid to hold onto early cancer detection company Grail
Listen: The anti-aging research boom, the Godfather of biotech,…
Listen: The anti-aging research boom, the Godfather of biotech, & the future of Biogen

Recommended Stories